Xinjiang Bai Hua Cun Pharma Tech Co Ltd banner

Xinjiang Bai Hua Cun Pharma Tech Co Ltd
SSE:600721

Watchlist Manager
Xinjiang Bai Hua Cun Pharma Tech Co Ltd Logo
Xinjiang Bai Hua Cun Pharma Tech Co Ltd
SSE:600721
Watchlist
Price: 8.65 CNY -2.7% Market Closed
Market Cap: ¥3.3B

P/B

4.1
Current
11%
More Expensive
vs 3-y average of 3.7

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
4.1
=
Market Cap
¥3.4B
/
Total Equity
¥801.8m

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
4.1
=
Market Cap
¥3.4B
/
Total Equity
¥801.8m

Valuation Scenarios

Xinjiang Bai Hua Cun Pharma Tech Co Ltd is trading above its 3-year average

If P/B returns to its 3-Year Average (3.7), the stock would be worth ¥7.81 (10% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-41%
Maximum Upside
No Upside Scenarios
Average Downside
24%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 4.1 ¥8.65
0%
3-Year Average 3.7 ¥7.81
-10%
5-Year Average 3.7 ¥7.67
-11%
Industry Average 2.8 ¥5.8
-33%
Country Average 2.4 ¥5.11
-41%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close

Market Distribution

Higher than 73% of companies in China
Percentile
73nd
Based on 7 605 companies
73nd percentile
4.1
Low
0 — 1.5
Typical Range
1.5 — 3.9
High
3.9 —
Distribution Statistics
China
Min 0
30th Percentile 1.5
Median 2.4
70th Percentile 3.9
Max 1 172 445.9

Xinjiang Bai Hua Cun Pharma Tech Co Ltd
Glance View

Market Cap
3.3B CNY
Industry
Metals & Mining

Xinjiang Baihuacun Pharam Tech Co., Ltd. provides medical research and development services as a contract research organization (CRO). The company is headquartered in Urumqi, Xinjiang and currently employs 722 full-time employees. The firm's main business is the research and development, registration and application of small molecule chemicals and the development of peptide drugs. The firm is engaged in the early discovery and screening of new drugs, drug clinical trials, biological sample analysis, medicine testing services, active pharmaceutical ingredient (API) and intermediate supply. The firm is also engaged in leasing and property services. The firm mainly conducts business within the domestic market.

Intrinsic Value
3.62 CNY
Overvaluation 58%
Intrinsic Value
Price ¥8.65
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett